Valneva SE (VALN): Price and Financial Metrics
VALN Price/Volume Stats
Current price | $6.67 | 52-week high | $9.50 |
Prev. close | $7.79 | 52-week low | $3.62 |
Day low | $6.62 | Volume | 216,400 |
Day high | $7.31 | Avg. volume | 67,383 |
50-day MA | $4.89 | Dividend yield | N/A |
200-day MA | $6.34 | Market Cap | 542.01M |
VALN Stock Price Chart Interactive Chart >
Valneva SE (VALN) Company Bio
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
VALN Price Returns
1-mo | 52.63% |
3-mo | 46.27% |
6-mo | -15.74% |
1-year | -16.36% |
3-year | -80.15% |
5-year | N/A |
YTD | 52.56% |
2024 | -57.84% |
2023 | -18.48% |
2022 | -77.09% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...